JPMorgan Chase & Co’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-7,560
| Closed | -$175K | – | 5550 |
|
|
2020
Q4 | $175K | Sell |
7,560
-39,047
| -84% | -$904K | ﹤0.01% | 4183 |
|
|
2020
Q3 | $463K | Buy |
46,607
+7,354
| +19% | +$73.1K | ﹤0.01% | 3417 |
|
|
2020
Q2 | $585K | Buy |
39,253
+7,258
| +23% | +$108K | ﹤0.01% | 3246 |
|
|
2020
Q1 | $389K | Buy |
31,995
+17,856
| +126% | +$217K | ﹤0.01% | 3408 |
|
|
2019
Q4 | $223K | Buy |
14,139
+11,707
| +481% | +$185K | ﹤0.01% | 3770 |
|
|
2019
Q3 | $30K | Buy |
+2,432
| New | +$30K | ﹤0.01% | 4400 |
|